EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Novel insights into metabolic‐associated steatotic liver disease preclinical models

Rocío Montero-Vallejo iD, Douglas Maya-Miles, Javier Ampuero, Franz Martín, Manuel Romero-Gómez iD, Rocío Gallego-Durán iD

Liver International · 2024-03 · 44 (3) · 644-662

DOI: 10.1111/liv.15830 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 30.01.2024. Verfasst von Rocío Montero-Vallejo und 5 weiteren Autor:innen. Beteiligte Einrichtung: SeLiver Group, Instituto de Biomedicina de Sevilla/CSIC/Hospital Virgen del Rocío, Sevilla, Spain. Hauptthemen laut MEDLINE: Fatty Liver, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Consejería de Salud y Familias, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic‐associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverCarcinoma, HepatocellularLiver NeoplasmsAnimalsMiceLiver Cirrhosis

Stichwörter der Autor:innen

MASLDanimal modelsliver fibrosissteatohepatitis

Autor:innen und Institutionen

  • SeLiver Group, Instituto de Biomedicina de Sevilla/CSIC/Hospital Virgen del Rocío, Sevilla, Spain.
  • Hepatic and Digestive Diseases Networking Biomedical Research Centre (CIBERehd), Sevilla, Spain.
  • Digestive Diseases Unit, Hospital Universitario Virgen Del Rocío, Sevilla, Spain.
  • Andalusian Center of Molecular Biology and Regenerative Medicine-CABIMER, University Pablo Olavide-University of Seville-CSIC, Seville, Spain.
  • Biomedical Research Network on Diabetes and Related Metabolic Diseases-CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Rocío Montero-Vallejo, Manuel Romero-Gómez, Rocío Gallego-Durán

Förderung

  • Instituto de Salud Carlos III
  • Consejería de Salud y Familias, Junta de Andalucía

Zitieren

APA

Montero-Vallejo, R., Maya-Miles, D., Ampuero, J., Martín, F., Romero-Gómez, M., & Gallego-Durán, R. (2024). Novel insights into metabolic‐associated steatotic liver disease preclinical models. Liver International, 44(3), 644-662. https://doi.org/10.1111/liv.15830

Vancouver

Montero-Vallejo R, Maya-Miles D, Ampuero J, Martín F, Romero-Gómez M, Gallego-Durán R. Novel insights into metabolic‐associated steatotic liver disease preclinical models. Liver International. 2024;44(3):644-662. doi:10.1111/liv.15830

BibTeX
@article{MonteroVallejo2024,
  author = {Montero-Vallejo, Rocío and Maya-Miles, Douglas and Ampuero, Javier and Martín, Franz and Romero-Gómez, Manuel and Gallego-Durán, Rocío},
  title = {Novel insights into metabolic‐associated steatotic liver disease preclinical models},
  journal = {Liver International},
  year = {2024},
  volume = {44},
  number = {3},
  pages = {644--662},
  doi = {10.1111/liv.15830}
}
Kostenlos starten →